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EDITORIAL
Plasmin in renal interstitial fibrosis: Innocent or guilty?
Renal interstitial fibrosis is a sine qua non of chronic
renal disease leading to end-stage renal failure. De novo
activation of a-smooth muscle actin–positive myofibrob-
lasts that are either derived from interstitial fibroblasts,
or more commonly transdifferentiated from tubular ep-
ithelial cells, and consequently, accumulation of intersti-
tial matrix, are key features of renal interstitial fibrosis
[1, 2]. Plasminogen-plasmin, well-known for its central
role in intravascular fibrinolysis, plays a role in extravas-
cular proteolysis, whereby plasmin directly degrades ma-
trix or activates matrix metalloproteinases (MMP) to
limit the accumulation of collagen and other matrix pro-
teins. In contrast, plasmin may also be profibrogenic, by
virtue of its ability to recruit leukocytes [3], to activate
latent TGF-b directly, and/or to release TGF-b from stor-
age sites within matrix [4]. Theoretically, plasmin could
also contribute to interstitial fibrosis by activating MMP
to cause tubular basement membrane (TBM) disruption
and promote tubular epithelial-to-mesenchymal transi-
tion (EMT) [5] (Fig. 1). However, recent studies of plas-
minogen activators (tPA and uPA) and their inhibitor
(PAI-1) indicate that their involvement in renal intersti-
tial fibrosis may be independent of plasminogen-plasmin
[5, 6]. Against expectations, tPA was shown to be profi-
brotic by a cascade of events that leads to MMP-9 in-
duction, TBM destruction, and therefore, promotion of
EMT [5]. The profibrotic function of PAI-1, also shown
to be independent of plasminogen-plasmin, may involve
the recruitment of fibrosis-inducing cells, including my-
ofibroblasts and macrophages [6]. These findings raised
doubt about the involvement of plasmin in renal intersti-
tial fibrosis, despite its proven protective effect in cres-
centic glomerulonephritis [7].
Using mice genetically deficient in plasminogen (plg
−/−) in the unilateral ureteric obstruction (UUO) model,
Edgtton et al [8] have extended our understanding of
this system by providing convincing evidence that plas-
min is not protective in renal interstitial fibrosis. In fact,
as assessed biochemically rather than morphometrically,
fibrosis was less in plg −/− mice. How might plasmin be
profibrotic in this situation? The authors demonstrated
that macrophage accumulation was less in plg −/− mice,
confirming a role for plasmin in recruitment of leukocytes.
With respect to MMP activation, they found that plasmin
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did not activate MMP-9, but may have had at least some
role in activating MMP-2. Furthermore, and in contrast to
Yang et al in the same model [5], they found that plasmin
did activate TGF-b by demonstrating that plg −/− mice
had lower ratios of big-h3 (a TGF-b1–responsive gene)
to TGF-b1 mRNA than plg +/+ mice, confirming this as
a potential profibrogenic mechanism for plasmin in renal
interstitial fibrosis. Of interest, they were unable to show
any difference in the accumulation of myofibroblasts be-
tween plg +/+ mice and plg −/− mice.
The new observations of Edgtton et al, together with
other recent studies, have clearly demonstrated the com-
plex roles of the plasminogen-plasmin and MMP systems
in renal fibrosis. The activities of these systems are broad,
and not easily explained by their classic description as
proteolytic cascades. The net effects of these systems on
renal fibrosis depend on a balance between their profi-
brotic and antifibrogenic and fibrinolytic actions, and in
sum, they appear more likely to do harm than good. Re-
nal interstitial fibrosis results from a complex interplay of
pathogenic events, including recruitment of inflammatory
cells, tubular EMT, activation and accumulation of myofi-
broblasts, and excessive deposition of ECM. Many other
factors in addition to the plasminogen-plasmin system
are involved. As mentioned above, compelling evidence
indicates that interstitial myofibroblasts, derived in part
from tubular epithelial cells via EMT [2, 5], play a pivotal
role in renal interstitial fibrosis. It is interesting to wonder
about the role of plasminogen-plasmin and MMP systems
in tubular EMT. Although plasmin had no effect on my-
ofibroblast accumulation in Edgtton et al’s study, it must
be emphasized that, just as with the effect of plasmin on
fibrosis, any effect of plasmin on EMT would be expected
to be the net result of counterbalancing forces. In partic-
ular, it would be important to know the role of plasmin-
independent MMP-9 activation and plasmin-dependent
TGF-b activation, macrophage recruitment, and MMP-2
activation on tubular EMT, and whether these observa-
tions in UUO apply to other models of renal interstitial
fibrosis.
The overall effect of plasminogen-plasmin and MMP
systems in renal interstitial fibrosis is becoming clear, but
there are contradictory observations from different mod-
els and counterbalancing influences to reconcile. Much
more remains to be learned about the effect of individ-
ual components of these systems at the level of gene and
protein expression. Without this detailed knowledge, nei-
ther system presents an easy target for treatment of renal
interstitial fibrosis.
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Fig. 1. Proposed pathways by which plasmin may cause interstitial fibrosis. Abbreviations are: tPA, tissue type plasminogen activator; uPA,
urokinase-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; TBM, tubular basement membrane; ECM, extracellular matrix;
MMP, matrix metalloproteinase; Mφ, macrophage.
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